← Leaderboards
Mingnan Chen
Utah State Higher Education System--University Of Utah
$4,920,350
Attributed
$4,920,350
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $924K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,920,350 · 7
By mechanism
R01$2,694,925 · 1
R21$1,264,166 · 3
R00$721,357 · 1
K99$162,902 · 1
R03$77,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Utah State Higher Education System--University Of Utah
Same institution · by research overlap
- Jindrich N. Kopecek$15,322,903
- Danielle Green$167,400
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignCellsIn VivoPublic Health RelevanceDrug KineticsPharmaceutical PreparationsFutureImmuneLymphocyteTreatment StrategyImmune ResponseBindingPreventBaseAutoimmune DiseasesEngineeringSafetyImmunityPreservationInfectionEffector T CellMultiple SclerosisAlbuminsExperimental Autoimmune Encephalomyelitis
Grant awards (16)
PD-1 BiKE: Targeting and Depleting PD-1 Positive Cells for Autoimmune Disease Treatment$423,500
R21 · FY2025 · AI · contact PI
A 3-In-One Design of CAR Tregs for Robust Immunotolerance$423,500
R21 · FY2025 · AI · contact PI
Albumin-Amended Antibody Drug Conjugate (A3DC) for Immunosuppression$77,000
R03 · FY2025 · EB · contact PI
Targeted depletion of programmed death-1 positive cells, a method that not only stops autoimmune attack but also preserves adaptive immunity$912,099
R01 · FY2024 · AI · contact PI
Targeted depletion of programmed death-1 positive cells, a method that not only stops autoimmune attack but also preserves adaptive immunity$150,861
R01 · FY2023 · AI · contact PI
Targeted depletion of programmed death-1 positive cells, a method that not only stops autoimmune attack but also preserves adaptive immunity$531,480
R01 · FY2021 · AI · contact PI
Targeted depletion of programmed death-1 positive cells, a method that not only stops autoimmune attack but also preserves adaptive immunity$543,680
R01 · FY2020 · AI · contact PI
Targeted depletion of programmed death-1 positive cells, a method that not only stops autoimmune attack but also preserves adaptive immunity$556,805
R01 · FY2019 · AI · contact PI
Enhancing cytotoxic T lymphocyte (CTL) responses by directly loading CTL epitope vaccines onto MHC Class I complexes on the dendritic cell surface$228,000
R21 · FY2018 · EB · contact PI
Enhancing cytotoxic T lymphocyte (CTL) responses by directly loading CTL epitope vaccines onto MHC Class I complexes on the dendritic cell surface$189,166
R21 · FY2017 · EB · contact PI
Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles$240,836
R00 · FY2014 · CA · contact PI
Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles$231,799
R00 · FY2013 · CA · contact PI
Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles$248,722
R00 · FY2012 · CA · contact PI
Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles$62,599
K99 · FY2011 · CA · contact PI
Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles$19,601
K99 · FY2011 · CA · contact PI
Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles$80,702
K99 · FY2010 · CA · contact PI